FcRn augments induction of tissue factor activity by IgG-containing immune complexes.
Animals
Antibodies, Monoclonal, Humanized
/ immunology
Anticoagulants
/ toxicity
Antigen-Antibody Complex
Heparin
/ toxicity
Histocompatibility Antigens Class I
/ genetics
Humans
Immunoglobulin G
/ genetics
Male
Mice
Monocytes
/ immunology
Platelet Factor 4
/ genetics
Receptors, Fc
/ genetics
Thrombocytopenia
/ chemically induced
Thromboplastin
/ metabolism
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
04 06 2020
04 06 2020
Historique:
received:
14
04
2019
accepted:
03
03
2020
pubmed:
19
3
2020
medline:
10
2
2021
entrez:
19
3
2020
Statut:
ppublish
Résumé
Thromboembolism complicates disorders caused by immunoglobulin G (IgG)-containing immune complexes (ICs), but the underlying mechanisms are incompletely understood. Prior evidence indicates that induction of tissue factor (TF) on monocytes, a pivotal step in the initiation, localization, and propagation of coagulation by ICs, is mediated through Fcγ receptor IIa (FcγRIIa); however, the involvement of other receptors has not been investigated in detail. The neonatal Fc receptor (FcRn) that mediates IgG and albumin recycling also participates in cellular responses to IgG-containing ICs. Here we asked whether FcRn is also involved in the induction of TF-dependent factor Xa (FXa) activity by IgG-containing ICs by THP-1 monocytic cells and human monocytes. Induction of FXa activity by ICs containing IgG antibodies to platelet factor 4 (PF4) involved in heparin-induced thrombocytopenia (HIT), β-2-glycoprotein-1 implicated in antiphospholipid syndrome, or red blood cells coated with anti-(α)-Rh(D) antibodies that mediate hemolysis in vivo was inhibited by a humanized monoclonal antibody (mAb) that blocks IgG binding to human FcRn. IgG-containing ICs that bind to FcγR and FcRn induced FXa activity, whereas IgG-containing ICs with an Fc engineered to be unable to engage FcRn did not. Infusion of an α-FcRn mAb prevented fibrin deposition after microvascular injury in a murine model of HIT in which human FcγRIIa was expressed as a transgene. These data implicate FcRn in TF-dependent FXa activity induced by soluble and cell-associated IgG-containing ICs. Antibodies to FcRn, now in clinical trials in warm autoimmune hemolytic anemia to lower IgG antibodies and IgG containing ICs may also reduce the risk of venous thromboembolism.
Identifiants
pubmed: 32187355
pii: S0006-4971(20)61980-2
doi: 10.1182/blood.2019001133
pmc: PMC7273830
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Anticoagulants
0
Antigen-Antibody Complex
0
Histocompatibility Antigens Class I
0
Immunoglobulin G
0
Receptors, Fc
0
Platelet Factor 4
37270-94-3
Heparin
9005-49-6
Thromboplastin
9035-58-9
Fc receptor, neonatal
TW3XAW0RCY
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2085-2093Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL142122
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL131626
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL141462
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK034854
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL125422
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL139448
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL128895
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL068835
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL123098
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL151467
Pays : United States
Organisme : NHLBI NIH HHS
ID : P01 HL139420
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK053056
Pays : United States
Informations de copyright
© 2020 by The American Society of Hematology.
Références
Ann Rheum Dis. 2015 Jun;74(6):1011-8
pubmed: 24464962
Blood. 2004 Nov 15;104(10):3173-80
pubmed: 14764524
J Immunol. 2011 Apr 15;186(8):4674-86
pubmed: 21402891
Blood. 2010 Dec 2;116(23):5021-31
pubmed: 20724543
Mol Biol Cell. 2013 Aug;24(15):2398-405
pubmed: 23741050
Br J Haematol. 2014 Jan;164(2):165-76
pubmed: 24180619
Blood. 2006 Mar 15;107(6):2346-53
pubmed: 16304054
Blood. 2016 Jan 28;127(4):464-72
pubmed: 26518435
Blood. 2006 Nov 15;108(10):3573-9
pubmed: 16849638
Nature. 1994 Nov 24;372(6504):336-43
pubmed: 7969491
Clin Exp Immunol. 2011 Feb;163(2):189-98
pubmed: 21091668
J Cell Sci. 2003 Feb 1;116(Pt 3):537-50
pubmed: 12508114
Thromb Haemost. 2001 May;85(5):903-7
pubmed: 11372686
J Immunol. 1995 Jun 15;154(12):6246-51
pubmed: 7759862
Blood. 2005 Jan 1;105(1):131-8
pubmed: 15304392
Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9337-42
pubmed: 18599440
J Immunol. 2004 Feb 15;172(4):2021-9
pubmed: 14764666
Sci Rep. 2018 Mar 23;8(1):5141
pubmed: 29572538
N Engl J Med. 2015 Jul 16;373(3):252-61
pubmed: 26176382
J Thromb Haemost. 2003 Jan;1(1):60-8
pubmed: 12871540
J Thromb Haemost. 2013 May;11(5):911-8
pubmed: 23480518
Sci Transl Med. 2017 Nov 1;9(414):
pubmed: 29093180
J Clin Invest. 2018 Oct 1;128(10):4372-4386
pubmed: 30040076
J Thromb Haemost. 2014 May;12(5):779-91
pubmed: 24612386
Blood. 2015 Apr 9;125(15):2397-404
pubmed: 25680756
Science. 1983 Dec 9;222(4628):1129-32
pubmed: 6648524
Thromb Res. 2015 Nov;136(5):1013-7
pubmed: 26359320
MAbs. 2012 Mar-Apr;4(2):208-16
pubmed: 22453095
Blood. 2018 May 10;131(19):2097-2110
pubmed: 29500169
Blood Rev. 2017 Nov;31(6):406-417
pubmed: 28784423
Clin Pharmacol Ther. 2019 Apr;105(4):1031-1039
pubmed: 30402880
Nat Commun. 2015 Sep 22;6:8277
pubmed: 26391892
J Thromb Haemost. 2019 Feb;17(2):271-282
pubmed: 30618125
Placenta. 2012 Jul;33(7):540-7
pubmed: 22538230
J Biol Chem. 1994 Dec 23;269(51):32435-40
pubmed: 7798242
J Biol Chem. 2001 Mar 2;276(9):6591-604
pubmed: 11096108
Proc Natl Acad Sci U S A. 2017 Apr 4;114(14):E2862-E2871
pubmed: 28330995
Blood. 2001 Oct 15;98(8):2442-7
pubmed: 11588041
J Immunol. 2001 Mar 1;166(5):3266-76
pubmed: 11207281
Lancet. 1966 Nov 19;2(7473):1087-93
pubmed: 4162525
Arthritis Rheumatol. 2014 Aug;66(8):2270-80
pubmed: 24692206
Immunity. 2013 Dec 12;39(6):1095-107
pubmed: 24290911
Blood. 2005 Mar 1;105(5):1964-9
pubmed: 15471954
Sci Adv. 2019 Dec 18;5(12):eaax9586
pubmed: 31897428
Proc Natl Acad Sci U S A. 1996 May 28;93(11):5512-6
pubmed: 8643606
Blood. 2000 Mar 1;95(5):1533-40
pubmed: 10688805
J Clin Invest. 2017 Mar 1;127(3):1090-1098
pubmed: 28218620
Proc Natl Acad Sci U S A. 2011 Jun 14;108(24):9927-32
pubmed: 21628593
Br J Haematol. 2016 Jan;172(1):144-6
pubmed: 25941063
J Immunol. 2000 May 15;164(10):5313-8
pubmed: 10799893
J Thromb Haemost. 2015 Oct;13(10):1928-40
pubmed: 26264622
Blood. 2018 Aug 16;132(7):727-734
pubmed: 29914979